Sajid Khan Selected Research

Proteolysis Targeting Chimera

1/2022	Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL-Specific Degrader DT2216.
1/2022	BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers.
11/2021	Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.
1/2021	Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells.
1/2020	DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.
1/2020	PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
1/2020	Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
1/2020	PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sajid Khan Research Topics

Disease

24	Neoplasms (Cancer) 01/2022 - 12/2013
9	Breast Neoplasms (Breast Cancer) 01/2021 - 12/2013
7	Neoplasm Metastasis (Metastasis) 09/2020 - 01/2015
6	Carcinogenesis 04/2020 - 12/2013
4	Leukemia 11/2021 - 01/2017
4	Thrombocytopenia (Thrombopenia) 01/2021 - 12/2019
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 02/2016
3	COVID-19 05/2021 - 01/2021
3	Lung Neoplasms (Lung Cancer) 01/2017 - 06/2015
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 01/2022
2	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 01/2018
2	Hematologic Neoplasms (Hematological Malignancy) 01/2020 - 01/2020
1	Genomic Instability 01/2022
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 08/2021
1	Arrhythmogenic Right Ventricular Dysplasia (Arrhythmogenic Right Ventricular Cardiomyopathy) 08/2021
1	Rheumatoid Arthritis 08/2021
1	Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy) 08/2021
1	Osteoarthritis 08/2021
1	Bites and Stings (Sting) 01/2021
1	Melanoma (Melanoma, Malignant) 01/2021
1	Diabetes Mellitus 09/2020
1	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 04/2020
1	T-Cell Lymphoma (Lymphoma, T Cell) 01/2020
1	Adenocarcinoma 01/2020
1	Infections 01/2020
1	Drug-Related Side Effects and Adverse Reactions 12/2019
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2017
1	Hypoxia (Hypoxemia) 10/2016
1	Pulmonary Hypertension 10/2016
1	Pulmonary Arterial Hypertension 10/2016
1	Triple Negative Breast Neoplasms 05/2016
1	Pain (Aches) 05/2016

Drug/Important Bio-Agent (IBA)

8	Proteolysis Targeting ChimeraIBA 01/2022 - 01/2020
8	Proteins (Proteins, Gene)FDA Link 01/2022 - 10/2016
7	snake venom protein C activatorIBA 01/2022 - 12/2019
6	Pharmaceutical PreparationsIBA 05/2021 - 01/2015
5	PhytochemicalsIBA 05/2021 - 01/2015
4	DT2216IBA 01/2022 - 12/2019
3	RNA (Ribonucleic Acid)IBA 08/2021 - 01/2015
3	Oral ContraceptivesIBA 09/2020 - 01/2015
3	CentchromanIBA 09/2020 - 01/2015
3	navitoclaxIBA 04/2020 - 12/2019
3	DNA (Deoxyribonucleic Acid)IBA 01/2017 - 06/2015
3	cucurbitacin BIBA 02/2016 - 06/2015
3	Matrix Metalloproteinases (MMPs)IBA 01/2016 - 01/2015
2	Annexin A5IBA 01/2022 - 01/2022
2	Peptides (Polypeptides)IBA 01/2021 - 01/2021
2	Small Interfering RNA (siRNA)IBA 09/2020 - 02/2016
2	CateninsIBA 09/2020 - 02/2016
2	EnzymesIBA 04/2020 - 01/2015
2	Apoptosis Regulatory ProteinsIBA 04/2020 - 01/2020
2	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 04/2020 - 01/2020
2	Ligases (Synthetase)IBA 01/2020 - 01/2020
2	Biological ProductsIBA 01/2020 - 01/2018
2	ChromatinIBA 01/2017 - 11/2016
2	MethyltransferasesIBA 06/2016 - 06/2015
2	Histone Deacetylases (Histone Deacetylase)IBA 06/2016 - 06/2015
2	4- (N- methyl- N- nitrosamino)- 1- (3- pyridyl)- 1- butanoneIBA 02/2016 - 06/2015
2	TriterpenesIBA 02/2016 - 01/2016
1	Gemcitabine FDA Link 01/2022
1	DNA Transposable Elements (Element, IS)IBA 01/2022
1	sotorasibIBA 01/2022
1	RNA Polymerase II (RNA Polymerase B)IBA 08/2021
1	Proteasome Endopeptidase Complex (Proteasome)IBA 08/2021
1	Fluorouracil (Carac)FDA LinkGeneric 01/2021
1	Interferon Type IIBA 01/2021
1	Amino Acids FDA Link 01/2021
1	FlavonoidsIBA 01/2021
1	Antiviral Agents (Antivirals)IBA 01/2021
1	AnthraquinonesIBA 01/2021
1	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 01/2021
1	Monomeric GTP-Binding ProteinsIBA 09/2020
1	Amygdalin (Laetrile)IBA 09/2020
1	LigandsIBA 01/2020
1	Antineoplastic Agents (Antineoplastics)IBA 12/2019
1	MicroRNAs (MicroRNA)IBA 01/2017
1	Inositol (Myoinositol)IBA 01/2017
1	BoratesIBA 01/2017
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2017
1	Doxycycline (Periostat)FDA LinkGeneric 01/2017
1	Inositol 1,4,5-Trisphosphate Receptors (Inositol Triphosphate Receptor)IBA 01/2017
1	diphenyl (biphenyl)IBA 01/2017
1	CarcinogensIBA 11/2016
1	Histones (Histone)IBA 11/2016
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 10/2016
1	WortmanninIBA 10/2016
1	AminopropionitrileIBA 10/2016
1	Messenger RNA (mRNA)IBA 10/2016
1	Protein-Lysine 6-Oxidase (Lysyl Oxidase)IBA 10/2016
1	CollagenIBA 10/2016
1	Zoledronic Acid (Zometa)FDA Link 05/2016
1	Metalloproteases (Metalloproteinases)IBA 05/2016
1	IodineIBA 05/2016

Therapy/Procedure

14	Therapeutics 01/2022 - 12/2002
3	Drug Therapy (Chemotherapy) 01/2021 - 07/2002
1	Immunotherapy 01/2021
1	Operative Surgical Procedures 01/2020
1	Adjuvant Chemotherapy 01/2017
1	Caloric Restriction 06/2016
1	Neoadjuvant Therapy 05/2016